Exercise therapy for the prevention of chemotherapy-induced peripheral neuropathy

Not Applicable

• Conditions: C00-C97; G62.0; Malignant neoplasms; Drug-induced polyneuropathy

• Registration Number: DRKS00011518
• Lead Sponsor: niversitätsklinik und Poliklinik für Innere Medizin IV

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-01-20
• Study Completion: 2018-05-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 17

Inclusion Criteria

histologically confirmed tumor diagnosis (main diagnosis), therapy with platinum derivatives, taxanes or vincristine, living in Halle or in the immediate surroundings, adequate mobility and autonomy, written consent

Exclusion Criteria

no suitability for participation in the study from the medical point of view, Relevant disturbance of pallesthesia (tuning fork) / pre-existing polyneuropathy, lack of german language skills

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
change of patient-reported quality of life (questionnaire: EORTC-QLQ-CIPN20) between baseline (week 0, t1), end of intervention (week 12, t2) and follow-up (week 16, t3)

Secondary Outcome Measures

Name	Time	Method
change of quality of life (EORTC-QLQ-C30), neuropathy related pain (Pain-Detect), pallesthesia (tuning fork), sensory disburtance (numbness, tingling, temperature), electrical impulses of muscles (electromyographie, MUAP), nerve conduction velocity and sympathetic skin response (electroneurography), mobility (TUGT), postural control (posturographic, IBS Tetrax), <br>muscular proprioceptive reflex (patellar/achilles) and neuropathy scores (CTC AE 4.3, Total Neuropathy Score) between baseline (week 0, t1), end of intervention (week 12, t2) and follow-up (week 16, t3)